On July 1, 2026, Hims & Hers Health disclosed in an SEC 8-K filing that it had established a $400 million Master Receivables Purchase Agreement with JPMorgan Chase Bank, allowing the telehealth company to sell eligible receivables to JPMorgan for cash, subject to a purchase discount and the bank's discretion on which receivables it buys. The facility runs an initial 364-day term with the option for one-year extensions, and Hims & Hers issued a performance undertaking covering its sellers' obligations under the deal.

Why It Matters

Receivables purchase facilities are a working-capital tool, not a growth-equity raise — they let a company convert what it's owed by insurers, PBMs, or patients into cash faster, smoothing the lag between delivering care and collecting payment. For a subscription telehealth business scaling into insurance-adjacent categories (weight loss, hormone therapy) where reimbursement cycles are slower and more complex than pure cash-pay ED prescriptions, that liquidity lever matters more than it would for a simpler DTC brand. It's also a signal of how large the male/female sexual- and hormonal-health telehealth category has become: a $400M receivables facility implies a receivables book big enough to make that kind of structured financing worth JPMorgan's while.

To make room for the new arrangement, the company also executed Amendment No. 4 to its existing Revolving Credit and Guaranty Agreement (signed June 26, 2026), adding a $400 million permitted-indebtedness basket and updating lien and collateral provisions — without changing the interest rate, fees, or core covenants on the revolver itself. Taken together, the two moves are structured to monetize the company's receivables book for near-term liquidity while keeping its existing credit facility intact and compatible with the new program.

The market reaction was immediate: HIMS shares jumped as much as 8% on the news, with analysts also pointing to accompanying price-target increases (Canaccord Genuity raised its target to $40) as a factor in the rally. The financing news lands the same week LifeMD announced its own testosterone-therapy telehealth push and while Hims & Hers continues expanding beyond its original ED/hair-loss base into weight management, menopause care, and specialty men's health verticals following its ~$1.15B Eucalyptus acquisition.

Sources

Update — 2026-07-02

Initial entry — story first created.